Stefano Pallanti is a chair of the CINP Neuromodulation Global Networking Community.

He is a physician–neuroscientist who applies advanced neuroscience to clinical practice. He is internationally recognised for his expertise in anxiety, obsessive–compulsive disorder, and neuromodulation treatments, including transcranial magnetic stimulation (TMS).

He is Professor of Psychiatry at Albert Einstein College of Medicine and Imperial College London. He previously served as Professor of Psychiatry and TMS Consultant at Stanford University and founded and directed the Strategic Centre of Excellence of Psychiatry at the Icahn School of Medicine at Mount Sinai. He is Medical and Scientific Director of the Institute of Neuroscience, Italy.

He is a NIMH grant co-PI in Theta Burst Stimulation of pathological gamblers, PI for Italy of the European Cooperation in Science & Technology (COST) CA16207 funding – European Network for Problematic Usage of the Internet (EU-PUI), and Beneficiary for Italy for the Horizon Grant, European Health and Digital Executive Agency: “Boosting Societal Adaptation and Mental Health in a Rapidly Digitalizing, Post-Pandemic Europe".

Dr. Pallanti serves on many distinguished boards and advisory councils, including the European Commission for Depression Treatments, the World Health Organization as an expert on Anxiety, European College of Neuropsychopharmacology, International Center for Autism Research and Education, International College of Obsessive-Compulsive Spectrum Disorders, and American Psychiatric Association for the Diagnostic and Statistical Manual of Mental Disorders for DSM-IV and DSM-5.

He is a member of the World Health Organization funded COVID-19 Clinical Research Coalition’s Ethics Working Group, the Good Clinical Practice Alliance – Europe (GCPA).

He is Editor of Archive of Behavioral Addiction, Deputy Editor of CNS Spectrums, where he is also a columnist. Dr. Pallanti is the author of more than 400 peer-reviewed scientific publications, 14 books, and four psychiatry manuals including Clinical Manual for Treatment of Schizophrenia published by American Psychiatric Publishing.

Professor Hickie is a Professor of Psychiatry, Co-Director of Health and Policy, Brain and Mind Centre, University of Sydney and Scientific Advisor for Innowell Pty Ltd. He has led major public health and health services developments in Australia, particularly focusing on early intervention for young people with depression, suicidal thoughts and behaviours and complex mood disorders. He is active in the development through codesign, implementation and continuous evaluation of new health information and personal monitoring technologies to drive highly-personalized and measurement-based care.

Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD. He has conducted an extensive series of clinical trials and experimental studies developing new treatments for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease. He has authored over 600 journal articles and several books, been cited nearly 40,000 times, established multiple clinical rTMS services and founded several device and clinical service companies.

Shinichiro Nakajima, MD, PhD, is a psychiatrist and Senior Assistant Professor in the Department of Neuropsychiatry at Keio University School of Medicine, Japan. He received his MD and PhD from Keio University and completed clinical and research fellowships at the Centre for Addiction and Mental Health in Toronto. His research focuses on clinical psychopharmacology, neuroimaging, computational psychiatry, and transcranial magnetic stimulation in mood disorders and schizophrenia, with particular interests in treatment resistance and the development of new treatment approaches.  

Dr Mohammed Khamis Al-Balushi is a dual board-certified psychiatrist through the Oman Medical Specialty Board and the Arab Board of Health Specializations based at Al-Massarah Hospital, Ministry of Health, Oman, and is currently a Clinical Fellow in Mood, Anxiety and Neuromodulation at the Institute of Mental Health, Singapore. His research spans TMS, esketamine and treatment-resistant depression; obsessive-compulsive disorder; medication adherence; community mental health service integration; and psychological outcomes following critical illness. His TMS research includes a scoping review of TMS studies in the Arab world and a study of psychiatrists’ knowledge and attitudes toward TMS in Oman. His clinical interests include mood disorders, neuromodulation and the implementation of evidence-based mental health services.

Prof Enrico Smeraldi is emeritus professor of psychiatry at Vita-Salute San Raffaele University and one of the leading figures in Italian biological psychiatry. His work has focused on mood disorders, psychopharmacology, chronobiology, and translational psychiatric research. At San Raffaele, he helped foster the clinical and scientific development of rTMS in Italy, including early controlled research in treatment-resistant depression.

Dr Alessandro Sarzetto is an Italian psychiatrist and researcher trained at Vita-Salute San Raffaele University. His interests include mood and anxiety disorders, chronobiological treatments, rTMS, eating disorders, sleep, and biomarkers of depression and suicidality. He currently works in the Treviso area, combining clinical psychiatry with research.

Dr. Siegfried Kasper is Professor of Psychiatry and was Head of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. He serves/ed on the executive committees and advisory boards of several national and international societies, such as the European College of Neuropsychopharmacology (ECNP), the European Psychiatric Association (EPA), World Federation of Societies of Biological Psychiatry (WFSBP) and the International College of Neuropsychopharmacology (CINP). Moreover he was Chair of the World Psychiatric Association (WPA) Section of Pharmacopsychiatry. He was Chief-Editor of the World Journal of Biological Psychiatry and the International Journal of Psychiatry in Clinical Practice.

Professor Abraham Zangen is the head of the brain stimulation and behavior lab and the chair of the psychobiology brain program at the Ben-Gurion University in Israel. Following his first degree in the medical school of the Hebrew University (1988-1992), his M.Sc (1993-1994) and Ph.D. studies (1996-1999) in neurosciences took place in Bar Ilan University and the Weizmann Institute of Science. His Ph.D. studies suggested a direct role for neuroplasticity in the brain reward system in the mechanism of antidepressant action. During his postdoctoral studies at the National Institute on Drug Abuse, NIH (1999-2003) with Roy Wise he identified specific triggers zones in the rat brain for rewarding effects of neuropeptides and cannabis. He also studied mechanisms of brain stimulation reward using microdialysis and measurements of neuropeptides in rats, and in parallel developed with Mark Hallett (NINDS, NIH), a special electromagnetic coil allowing deep transcranial magnetic stimulation (DTMS) in humans. In 2003 he returned to Israel and established his lab in the Weizmann Institute, in the department of neurobiology and was promoted to the rank of Associate Professor in 2010. In 2012 he joined the Ben-Gurion University and in 2015 was promoted to the rank of Full Professor. Since his return to Israel Dr. Zangen is studying mechanisms of altered neuroplasticity in depression, addiction and impaired attention, and the effects of repeated brain stimulation on markers for neuroplasticity and on behavioral outcomes in both animal models and humans. He is also studying electrophysiological outcomes and potential clinical effectiveness of the unique DTMS coil he has developed for the treatment of depression, addiction, OCD and ADHD. The device he has developed for the treatment of depression targeting deep dorsolateral and ventrolateral prefrontal cortex areas was approved by the FDA in 2014 and treated over 200,000 patients worldwide. A different version of his DTMS coil targeting the anterior cingulate cortices was approved by the FDA in 2018 for OCD treatment. In 2020, another DTMS coil he developed that targets the lateral prefrontal and insular cortices was approved by the FDA for nicotine addiction following an international multicenter study in which Prof. Zangen was the PI. His early work in this field led to establishment of Brainsway in 2003, a company that commercializes the coils that he has developed with his colleagues.

Prof. Zangen has published over 200 peer-reviewed articles, reviews and book chapters. His current H-factor is 73. His scientific work was rewarded with 12 different personal prizes including the Medical Futures Innovation Award in London (2007), the Sieratzki-Korczyn prize for advances in neurosciences (2010), the CME award (2012), The Joludan Prize (2015), The Innovation Award of Ben Gurion University (2019), and he has received several distinguished research grants including NIH, European Horizon, ISF and BSF funding for his research.

Professor Risto Ilmoniemi works as Senior Advisor at the Department of Neuroscience and Biomedical Engineering at Aalto University. His current research focuses on advancing transcranial magnetic stimulation (TMS) technologies for both neuroscience research and clinical applications. He leads the development of multi-locus TMS (mTMS) in the ERC Synergy project ConnectToBrain. Co-author of the book Brain Signals (MIT Press, 2019), he combines biomedical engineering, neuroscience, and mathematical modeling to improve brain signal analysis and the interpretation of neurophysiological data. Professor Ilmoniemi is the founder and former CEO of Nexstim Plc, the company that commercialized navigated TMS (nTMS) and TMS–EEG. He also co-founded the company Cortisys, which develops and markets mTMS systems. Recognized for his work in magnetoencephalography (MEG), TMS, and neurophysiology, he received in 2024 the Jenny and Antti Wihuri Foundation Honorary Prize. He is Distinguished Professor emeritus in Applied Physics at Aalto University, Honorary Doctor of the University of Helsinki, and Novo Nordisk Foundation Distinguished Innovator and Ambassador.

Dr Goh Shih Ee is Consultant Psychiatrist and Head of the Neurostimulation Service at the Institute of Mental Health, Singapore. His clinical practice focuses on mood and anxiety disorders, and neuromodulation therapies including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), and ketamine treatment. He has collaborated on clinical research evaluating accelerated and personalised TMS protocols in Singapore and had developed the ketamine service in IMH.

Adj A/Prof Tor Phern-Chern is Director of Interventional Psychiatry Services and Senior Consultant at the National University Hospital, Singapore, and Adjunct Associate Professor at the National University of Singapore. He established Singapore's first dedicated neurostimulation service and is internationally recognised for his work in TMS, ECT, and precision neuromodulation, with more than 80 peer-reviewed publications. He currently serves as Treasurer of the International Society of ECT and Neurostimulation and has been instrumental in advancing interventional psychiatry and neurostimulation research across Singapore and the region.

Leigh van den Heuvel is a neuropsychiatrist and leads the neuropsychiatry unit at Tygerberg Hospital in Cape Town, South Africa. She is an associate professor the Stellenbosch University Department of Psychiatry and leads the department’s transcranial magnetic stimulation (TMS) service. Her research interests include trauma, stress, psychoneuroendocrinology, neuropsychiatry, and healthcare worker wellness.

Dr Erine Bröcker is a clinical psychologist and early-career researcher in the Department of Psychiatry at Stellenbosch University. Her skill set spans neuromodulation (e.g., transcranial magnetic stimulation), trauma and stress-related disorders, digital mental health interventions, and geriatric psychiatry. Her current skill set further includes clinical research, interventional trial design, project administration, clinical monitoring, and neurocognitive assessments.

Joseph J. Taylor, MD, PhD, is a neuroscientist and board-certified psychiatrist specializing in brain stimulation and interventional psychiatry. He is an Assistant Professor of Psychiatry at Harvard Medical School and holds the Jonathan F. Borus, MD Endowed Chair in Psychiatry at Mass General Brigham, where he serves as Director of Noninvasive Neuromodulation Clinical Trials. At Brigham and Women’s Hospital, he is Medical Director of TMS in the Center for Brain Circuit Therapeutics, Director of the Interventional Psychiatry Research Program, and Associate Program Director and Research Track Co-Director of the Psychiatry Residency Program. His research prospectively tests candidate brain stimulation targets in clinical trials, with a particular focus on whether neuroimaging-guided treatment can improve clinical outcomes. This research has been supported by the National Institutes of Health, Howard Hughes Medical Institute, Sidney R. Baer, Jr. Foundation, Baszucki Group, Brain & Behavior Research Foundation, Home Base Foundation, Harvard Medical School, and Mass General Brigham.

TBA

Giovanni Martinotti is a Full Professor of Psychiatry at the "G. d’Annunzio" University of Chieti–Pescara and a Lecturer in Psychiatry at LUMSA University and Saint Camillus International University in Rome. He is the author of more than 400 scientific publications and is listed in the SCOPUS database with an H-index of 68. For four consecutive years, he has been included by Stanford University among the world’s top 2% most influential academic scientists.

He serves as Editor for several international journals, including Comprehensive Psychiatry and Current Neuropharmacology. He is currently a member of the National Board of the Italian Society of Psychiatry (SIP) and Chair of the Ecology, Psychiatry and Mental Health Section of the World Psychiatric Association (WPA).

His research focuses on addiction psychiatry, brain stimulation techniques, new psychoactive substances, treatment-resistant depression, and the emerging field of psychedelic-based therapeutics.

TBA

Dr. Camprodon is Chief of the Division of Neuropsychiatry and Interventional Psychiatry at Mass General Brigham and Associate Professor of Psychiatry and Neurology at Harvard Medical School.

Clinically, he is the founding director of the MGH Transcranial Magnetic Stimulation (TMS) clinical service, co-director of the MGH Psychiatric Neurosurgery Committee, and an attending physician in the departments of Psychiatry (Neuropsychiatry) and Neurology (Cognitive and Behavioral Neurology). He created and now co-directs the MGH clinical fellowship in Interventional Neuropsychiatry and Neuromodulation, the first of its kind in the country, and is board-certified in Psychiatry and Behavioral Neurology & Neuropsychiatry

Scientifically, he directs the Laboratory for Circuit Neuroscience and Neuromodulation and serves as a founding member of the executive committee for the MGH Interdisciplinary Brain Center. His work uses multimodal combinations of neuromodulation (noninvasive, convulsive, and surgical), neuroimaging, neurophysiology, behavioral, and clinical methods to investigate brain circuits and plasticity. The scope of his research includes basic, translational, and clinical projects focused on human circuit neuroscience. Projects in his laboratory address (1) the anatomy, physiology, and behavioral computations of disease-relevant networks, (2) the investigation of pathophysiological mechanisms at the circuit level (with an emphasis on transdiagnostic processes and the role of plasticity), and (3) the translational and clinical development of tools to support clinical care and decision-making (e.g., biomarker discovery and treatment development). Critical efforts are geared towards applying paradigms and methods from human systems/cognitive neuroscience to discover treatment targets and develop individualized precision circuit therapeutics, with an emphasis on device neuromodulation.

Jean-Marie Batail is Professor of Psychiatry, with clinical and research expertise in mood disorders and obsessive–compulsive disorder. His research focuses on neuromodulation for psychiatric disorders, biomarkers in psychiatry, and neuroimaging. He is particularly involved in research aiming to personalise non-invasive brain-stimulation treatments, especially transcranial magnetic stimulation (TMS) for depression.

Fidel Vila-Rodriguez is an Associate Professor and Co-Head of the Interventional Brain Medicine Program in the Department of Psychiatry, and an Associate Member of the School of Biomedical Engineering at the University of British Columbia.

As a clinician-scientist, he has a strong interest in translational research that bridges the understanding of the neurobiology of psychiatric disorders with the clinical applications of this knowledge. His clinical practice focuses on those most severely affected by these conditions, and his research seeks novel therapeutic interventions to help alleviate the suffering of people with severe and refractory forms of psychosis and depression.

He strongly believes that understanding the mechanisms of action of non-invasive neurostimulation therapies (NINETs) is a critical step towards translating research knowledge into clinical practice. Applying this knowledge can have a direct, immediate and positive impact on the lives of those living with the most devastating forms of mental illness and their families.

Salvador Dura-Bernal is an Associate Professor in Computational Neuroscience at the State University of New York (SUNY) Downstate, a Research Scientist at the Nathan Kline Institute for Psychiatric Research, and the Director of the Global Center for AI in Mental Health. He completed his PhD and first postdoc at the University of Plymouth, UK; followed by postdocs at Johns Hopkins and SUNY Downstate.

Dr. Dura-Bernal leverages AI and supercomputing to develop biophysically realistic simulations of the brain neural circuits to better understand and treat mental health diseases and disorders, such as schizophrenia, epilepsy, Alzheimer's, and spinal cord injury. With over 40 peer-reviewed publications, his work has been recognized by the scientific community, having been awarded multiple large research grants as Principal Investigator from the National Institutes of Health (NIH), the National Science Foundation (NSF), the NY State Spinal Cord Injury Board, and others.

Dr. Dura-Bernal has also received numerous awards and honors, including being selected as a Google Cloud Research Innovator for driving scientific breakthroughs, recognized with the Best Use of AI Award from HPCwire, and awarded the Robert Furchgott Scholar early career investigator prize.

For more information visit the Dura-Bernal Lab website: http://dura-bernal.org.

Sarah “Holly” Hollingsworth Lisanby, MD, DLFAPA, is Founding Dean and Foundation Professor of the Arizona State University (ASU) John Shufeldt School of Medicine and Medical Engineering and Professor Emeritus at Duke University School of Medicine. A translational psychiatrist and early pioneer in transcranial magnetic stimulation (TMS), she helped shape the field through research, clinical translation, engineering collaboration, and interdisciplinary mentorship.

She led the subgroup analysis that helped establish the basis for the first FDA clearance of TMS for depression, identifying benefit among patients who had not improved after one adequate antidepressant medication trial in the current episode. She subsequently contributed as Columbia’s principal investigator in the NIMH-funded OPT-TMS trial, evidence from which supported expansion of the clinical indication. Her research also helped establish rigorous sham controls and illuminate how cognitive context, task timing, and brain state influence stimulation effects.

Her team was one of the first to pursue electric-field modeling to understand how anatomy and stimulation parameters determine the dose delivered to the brain, alongside development of new coil device designs. She mentored engineers including Drs. Angel Peterchev, Stefan Goetz, and Zhi-De Deng, who have become leaders in neuromodulation. She led the translational development of magnetic seizure therapy (MST), advancing it from device development and preclinical studies through first-in-human and multicenter clinical trials, with the goal of retaining antidepressant efficacy while reducing cognitive adverse effects. Her work to modernize electroconvulsive therapy (ECT) includes research on pulse width, electrode configuration, electric-field distribution, and individualized current amplitude to improve the balance between therapeutic benefit and cognitive safety.

Dr. Lisanby founded brain stimulation programs at Columbia and Duke and was the first woman to chair Duke’s Department of Psychiatry and Behavioral Sciences. From 2015 to 2025, she founded and directed the Division of Translational Research at the National Institute of Mental Health and founded and directed the Noninvasive Neuromodulation Unit in the NIMH Intramural Research program. She co-led the NIH BRAIN Initiative team focused on large-scale neural recording and modulation and launched new programs to fund research on TMS and other neuromodulation technologies.

Her professional leadership includes the presidency of the International Society of Transcranial Stimulation; founding chair of the National Network of Depression Centers rTMS Work Group; leadership of the International Federation of Clinical Neurophysiology Brain Stimulation Special Interest Group; and service on the FDA Neurological Devices Panel. She was the first woman to be elected president of the Association for Convulsive Therapy, now the International Society for ECT and Neuromodulation, and chaired the American Psychiatric Association Task Force to Revise the Practice on Electroconvulsive Therapy (ECT). She is an elected member and Councilor of the Association of American Physicians.

Her honors include CINP’s Max Hamilton Memorial Prize, the American College of Neuropsychopharmacology (ACNP) Eva King Killam Award for Translational Research, the NARSAD (now Brain Behavior Research Foundation) Distinguished Investigator Award, the Gerald L. Klerman Award from the Depression and Bipolar Support Alliance, and NIH Director’s Awards. She is an elected Fellow of the American Institute for Medical and Biological Engineering and ACNP, a Distinguished Life Fellow of the American Psychiatric Association, and a Distinguished Fellow of the International Society for ECT and Neuromodulation.

As Founding Dean of the ASU John Shufeldt School of Medicine and Medical Engineering, she brings this experience in discovery, clinical translation, and innovation to building a new model for medical education at the convergence of engineering and medicine.